Nordblom Company Welcomes Augmenix to New Office/R&D Campus
Nordblom Company announced today that they have completed a 21,000 SF lease with Augmenix Inc. Augmenix is a privately held medical device company focused on the development and commercialization of radiation oncology and urology products using its proprietary hydrogel technology. They will move their corporate headquarters from Waltham to 201 Burlington Road in late 2016.
“201 Burlington was the ideal choice for Augmenix due to its easy access to Routes 3 and 128, proximity to surrounding amenities, and professional curb appeal,” said John Pedersen, CEO of Augmenix. “Recognized by Inc. 5000 as one of the fastest growing private companies in the nation and the metro Boston area, we are excited to be tripling our footprint in support of our growing operations and look forward to our new headquarters in Bedford.”
201 Burlington Road consists of two connected office buildings totaling 135,000 square feet. The buildings have received considerable improvements, including a complete demo-to-structure renovation which provides for a dramatic two-story atrium lobby, a new metal façade, energy efficient windows, advanced systems and attractive landscape work. Nordblom has also invested in a new, on-site cafe, bike storage, state-of-the-art fitness facility and shower/locker facilities to create a first class office campus. Nearby amenities include a wide range of restaurants and retail, as well as MBTA bus service at the front door accessing both the Lowell and Alewife train stations. Situated in the center of the Route 128/Route 3 Tech Corridor, 201 Burlington Road offers unparalleled access to the region’s central highways and prominent visibility from Route 3 at Exit 26.
“We are thrilled that Augmenix will be our newest growth company in this dynamic building,” commented Og Hunnewell, Partner at Nordblom Company. “They are the perfect tenant for this forward-looking property,” he continued.